Cadrenal Therapeutics (CVKD) Net Cash Flow (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Net Cash Flow of -$1.7 million for Q1 2026, down 1249.19% sequentially from $147707.0 in Q4 2025, and up 36.71% YoY from -$1.2 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Net Cash Flow (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 36.71% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 747.48% YoY) and the FY2025 annual result came in at -$6.0 million, down 472.04% from the prior year.
- Net Cash Flow slipped to -$1.7 million in Q1 2026 per CVKD's latest filing, from $147707.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $5.9 million in Q3 2023 and troughed at -$2.7 million in Q1 2025.
- A 5-year average of $136613.1 and a median of -$673274.0 in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 12761.79% in 2023, down 902.82% in 2023.
- Over 5 years, Net Cash Flow stood at -$70496.0 in 2022, then plunged by 902.82% to -$706945.0 in 2023, then surged by 900.71% to $5.7 million in 2024, then sank by 97.39% to $147707.0 in 2025, then sank by 1249.19% to -$1.7 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.7 million, $147707.0, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Cadrenal Therapeutics | 4.57 Mn | 2.17 Mn | - | 78,557.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,557.00 |
| Jun 30, 2026 | 78,557.00 |
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | 147,707.00 |
| Dec 31, 2025 | 147,707.00 |
| Sep 30, 2025 | -1.71 Mn |
| Sep 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -2.68 Mn |
| Mar 31, 2025 | -2.68 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | -673,274.00 |
| Sep 30, 2024 | -673,274.00 |
| Jun 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -1.53 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Mar 31, 2024 | -1.84 Mn |